Search

Your search keyword '"Laura Moran"' showing total 5 results
Start Over Author "Laura Moran" Journal american journal of respiratory and critical care medicine
5 results on '"Laura Moran"'

1. A Semimechanistic Model of the Bactericidal Activity of High-Dose Isoniazid against Multidrug-Resistant Tuberculosis: Results from a Randomized Clinical Trial

Author

Laura Moran, Elisa H. Ignatius, Susan Swindells, Paolo Denti, Richard Hafner, Florian von Groote-Bidlingmaier, Eric L. Nuermberger, Naadira Vanker, Soyeon Kim, Andreas H. Diacon, Kathleen Donahue, Kelly E. Dooley, Susan L. Rosenkranz, Kamunkhwala Gausi, Xin Sun, and Lubbe Wiesner

Subjects
Pulmonary and Respiratory Medicine, medicine.medical_specialty, Tuberculosis, biology, business.industry, Isoniazid, Phases of clinical research, Isoniazid resistance, bacterial infections and mycoses, Critical Care and Intensive Care Medicine, biology.organism_classification, medicine.disease, law.invention, Multiple drug resistance, Mycobacterium tuberculosis, Randomized controlled trial, law, Internal medicine, Medicine, business, medicine.drug
Abstract

Rationale: There is accumulating evidence that higher-than-standard doses of isoniazid are effective against low-to-intermediate-level isoniazid-resistant strains of Mycobacterium tuberculosis, but...

Published
2021
Full Text
View/download PDF

2. Early Bactericidal Activity of Different Isoniazid Doses for Drug-Resistant Tuberculosis (INHindsight): A Randomized, Open-Label Clinical Trial

Author

Kelly E. Dooley, Sachiko Miyahara, Florian von Groote-Bidlingmaier, Xin Sun, Richard Hafner, Susan L. Rosenkranz, Elisa H. Ignatius, Eric L. Nuermberger, Laura Moran, Kathleen Donahue, Susan Swindells, Naadira Vanker, Andreas H. Diacon, Rachel Issa, Christopher Lane, Mark Lojacono, Rachel Mahachi, William Murtaugh, Lynette Purdue, Akbar Shahkolahi, and Ronald Ssenyonga

Subjects
Pulmonary and Respiratory Medicine, medicine.medical_specialty, Tuberculosis, business.industry, INHA, Drug resistant tuberculosis, Isoniazid, Phases of clinical research, Isoniazid resistance, bacterial infections and mycoses, Critical Care and Intensive Care Medicine, medicine.disease, Clinical trial, Internal medicine, Correspondence, Medicine, Open label, business, medicine.drug
Abstract

Rationale: High-dose isoniazid is recommended in short-course regimens for multidrug-resistant tuberculosis (TB). The optimal dose of isoniazid and its individual contribution to efficacy against T...

Published
2020
Full Text
View/download PDF

3. Resistance-Conferring Mycobacterial Mutations and Quantification of Early Bactericidal Activity

Author

Susan Swindells, Rachel Mahachi, Florian von Groote-Bidlingmaier, Caryn Upton, William Murtaugh, Richard Hafner, Laura Moran, Xin Sun, Sachiko Miyahara, Solomon P. le Roux, Susan L. Rosenkranz, Andreas H. Diacon, Kathleen Donahue, Naadira Vanker, Kelly E. Dooley, Akbar Shahkolahi, Ronald Ssenyonga, Lynette Purdue, Eric L. Nuermberger, Mark Lojacono, Rachel Issa, Elisa H. Ignatius, and Christopher Lane

Subjects
Pulmonary and Respiratory Medicine, Resistance (ecology), business.industry, Antitubercular Agents, Mycobacterium tuberculosis, Original Articles, Critical Care and Intensive Care Medicine, Microbiology, Mutation, Tuberculosis, Multidrug-Resistant, Isoniazid, Medicine, Humans, business
Abstract

Rationale: High-dose isoniazid is recommended in short-course regimens for multidrug-resistant tuberculosis (TB). The optimal dose of isoniazid and its individual contribution to efficacy against TB strains with inhA or katG mutations are unknown. Objectives: To define the optimal dose of isoniazid for patients with isoniazid-resistant TB mediated by inhA mutations. Methods: AIDS Clinical Trials Group A5312 is a phase 2A, open-label trial in which individuals with smear-positive pulmonary TB with isoniazid resistance mediated by an inhA mutation were randomized to receive isoniazid 5, 10, or 15 mg/kg daily for 7 days (inhA group), and control subjects with drug-sensitive TB received the standard dose (5 mg/kg/d). Overnight sputum cultures were collected daily. The 7-day early bactericidal activity (EBA) of isoniazid was estimated as the average daily change in log(10) cfu on solid media (EBA(cfu0–7)) or as time to positivity (TTP) in liquid media in hours (EBA(TTP0–7)) using nonlinear mixed-effects models. Measurements and Main Results: Fifty-nine participants (88% with cavitary disease, 20% HIV-positive, 16 with isoniazid-sensitive TB, and 43 with isoniazid-monoresistant or multidrug-resistant TB) were enrolled at one site in South Africa. The mean EBA(cfu0–7) at doses of 5, 10, and 15 mg/kg in the inhA group was 0.07, 0.17, and 0.22 log(10) cfu/ml/d, respectively, and 0.16 log(10) cfu/ml/d in control subjects. EBA(TTP0–7) patterns were similar. There were no drug-related grade ≥3 adverse events. Conclusions: Isoniazid 10–15 mg/kg daily had activity against TB strains with inhA mutations similar to that of 5 mg/kg against drug-sensitive strains. The activity of high-dose isoniazid against strains with katG mutations will be explored next. Clinical trial registered with www.clinicaltrials.gov (NCT01936831).

Published
2020

4. Reply to Decroo

Author

Kelly E, Dooley, Sachiko, Miyahara, Florian, von Groote-Bidlingmaier, Xin, Sun, Richard, Hafner, Susan L, Rosenkranz, Elisa H, Ignatius, Eric L, Nuermberger, Laura, Moran, Kathleen, Donahue, Susan, Swindells, Naadira, Vanker, and Andreas H, Diacon

Subjects
Tuberculosis, Multidrug-Resistant, Correspondence, Isoniazid, Humans, Tuberculosis, Rifampin, Pyrazinamide
Published
2020

5. Reply to Decroo et al.: High-Dose First-Line Treatment Regimen for Recurrent Rifampicin-Susceptible Tuberculosis

Author

Susan Swindells, Andreas H. Diacon, Florian von Groote-Bidlingmaier, Kathleen Donahue, Naadira Vanker, Susan L. Rosenkranz, Richard Hafner, Elisa H. Ignatius, Laura Moran, Xin Sun, Sachiko Miyahara, Kelly E. Dooley, and Eric L. Nuermberger

Subjects
Pulmonary and Respiratory Medicine, medicine.medical_specialty, Tuberculosis, business.industry, Isoniazid, MEDLINE, Pyrazinamide, Critical Care and Intensive Care Medicine, medicine.disease, Multiple drug resistance, First line treatment, Regimen, Internal medicine, Medicine, business, Rifampicin, medicine.drug
Published
2020
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results